Design Therapeutics (DSGN) Competitors $6.21 -0.04 (-0.64%) (As of 12/23/2024 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DSGN vs. OCUL, MESO, TVTX, NTLA, PRAX, ARVN, ARDX, DAWN, SYRE, and CALTShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Praxis Precision Medicines (PRAX), Arvinas (ARVN), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), Spyre Therapeutics (SYRE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Praxis Precision Medicines Arvinas Ardelyx Day One Biopharmaceuticals Spyre Therapeutics Calliditas Therapeutics AB (publ) Design Therapeutics (NASDAQ:DSGN) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Do analysts prefer DSGN or OCUL? Design Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 12.72%. Ocular Therapeutix has a consensus target price of $16.71, indicating a potential upside of 95.26%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has preferable valuation and earnings, DSGN or OCUL? Design Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Design Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$66.86M-$0.85-7.31Ocular Therapeutix$61.44M21.90-$80.74M-$1.32-6.48 Does the media favor DSGN or OCUL? In the previous week, Ocular Therapeutix had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Ocular Therapeutix and 4 mentions for Design Therapeutics. Ocular Therapeutix's average media sentiment score of 0.97 beat Design Therapeutics' score of 0.69 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, DSGN or OCUL? Design Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Does the MarketBeat Community favor DSGN or OCUL? Ocular Therapeutix received 427 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 70.14% of users gave Ocular Therapeutix an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Ocular TherapeutixOutperform Votes43770.14% Underperform Votes18629.86% Is DSGN or OCUL more profitable? Design Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Design Therapeutics' return on equity of -18.01% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -18.01% -17.38% Ocular Therapeutix -283.74%-45.18%-30.87% Do insiders and institutionals hold more shares of DSGN or OCUL? 56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Comparatively, 3.5% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryOcular Therapeutix beats Design Therapeutics on 10 of the 17 factors compared between the two stocks. Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$351.62M$6.69B$5.20B$9.15BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-7.3110.4886.6917.11Price / SalesN/A193.651,148.16122.75Price / CashN/A57.1643.2337.84Price / Book1.255.134.804.78Net Income-$66.86M$151.58M$120.46M$225.43M7 Day Performance-0.64%-1.40%-0.93%-0.82%1 Month Performance10.50%-3.68%14.89%1.02%1 Year Performance132.58%9.07%29.57%15.72% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.9058 of 5 stars$6.21-0.6%$7.00+12.7%+132.6%$351.62MN/A-7.3140OCULOcular Therapeutix3.6921 of 5 stars$8.97+3.2%$16.71+86.3%+106.8%$1.41B$58.44M0.00267MESOMesoblast0.9768 of 5 stars$12.10+2.9%$11.50-5.0%+697.7%$1.38B$5.90M0.0080Analyst DowngradeNews CoverageGap UpTVTXTravere Therapeutics2.6052 of 5 stars$17.49+1.0%$22.62+29.3%+89.3%$1.37B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.1266 of 5 stars$13.36+3.6%$54.94+311.2%-61.4%$1.36B$36.28M-2.46600PRAXPraxis Precision Medicines2.2316 of 5 stars$72.06+2.7%$146.33+103.1%+281.0%$1.34B$2.45M-7.06110High Trading VolumeARVNArvinas1.8446 of 5 stars$19.00-2.6%$63.50+234.2%-54.6%$1.31B$78.50M-4.18445ARDXArdelyx3.9105 of 5 stars$5.39+3.3%$10.42+93.3%-27.9%$1.28B$251.85M-17.80267Insider TradeDAWNDay One Biopharmaceuticals1.506 of 5 stars$12.63-0.9%$35.71+182.8%-15.6%$1.27B$101.95M-12.3860Positive NewsSYRESpyre Therapeutics1.7908 of 5 stars$24.46+1.4%$51.50+110.5%+29.8%$1.26B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.0687 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies OCUL Alternatives MESO Alternatives TVTX Alternatives NTLA Alternatives PRAX Alternatives ARVN Alternatives ARDX Alternatives DAWN Alternatives SYRE Alternatives CALT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DSGN) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
